Olmesartán Tarbis (Olmesartan Medoxomil)

Olmesartan Medoxomil is an antihypertensive agent that acts on the renin‑angiotensin system to lower blood pressure.

• Hypertension: helps achieve target blood pressure and reduces cardiovascular risk.
• Diabetic nephropathy (adjunct): may slow progression of kidney damage when used with other therapies.
• Heart failure (off‑label): sometimes used to support blood‑pressure control in heart‑failure patients.
• Stroke prevention (off‑label): contributes to long‑term risk reduction in patients with prior cerebrovascular events.

• Olmesartan Medoxomil is a selective antagonist of the angiotensin II type 1 (AT1) receptor. By blocking AT1 receptors, it prevents angiotensin II‑mediated vasoconstriction, aldosterone secretion, and sympathetic activation, leading to vasodilation, reduced sodium and water retention, and ultimately lower systemic blood pressure.

Olmesartan Medoxomil may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dizziness
• Headache
• Fatigue
• Nasal congestion
• Diarrhea
• Back pain

Serious or Rare Side Effects

• Angio‑edema
• Hyperkalemia
• Acute kidney injury
• Severe hypotension
• Liver enzyme elevation
• Bullous pemphigoid

When prescribing Olmesartan Medoxomil, clinicians should consider several safety aspects.

• Renal function: assess baseline creatinine and monitor periodically.
• Electrolytes: check potassium levels, especially if combined with potassium‑sparing diuretics.
• Pregnancy: contraindicated in the second and third trimesters due to fetal toxicity.
• Elderly: start at lower dose and monitor for orthostatic hypotension.
• Drug interactions: review concomitant medications for additive blood‑pressure effects.
• Store at ambient temperature: keep in original packaging ; protect from moisture.

Olmesartan Medoxomil can interact with several medicines that affect blood pressure or renal function.

Major Interactions (Avoid)

• Aliskiren combined with any ARB in patients with diabetes or renal impairment.
• Potassium‑rich supplements and potassium‑sparing diuretics – risk of hyper‑kalaemia.
• Dual ACE‑inhibitor or ARB therapy – increased risk of renal dysfunction.

Moderate Interaction Monitor Closely

• Non‑steroidal anti‑inflammatory NSAIDs – may blunt antihypertensive effect.
• Lithium – may increase serum lithium levels.
• Cyclosporine – may raise olmens c‑ c  ...  ...   ...  ...  …  …